Literature DB >> 18836734

NSF, Unc-18-1, dynamin-1 and HSP90 are inclusion body components in neuronal intranuclear inclusion disease identified by anti-SUMO-1-immunocapture.

Dean L Pountney1, Mark J Raftery, Fariba Chegini, Peter C Blumbergs, Wei Ping Gai.   

Abstract

Neuronal intranuclear inclusion disease, a progressive ataxia that may be familial or sporadic, is characterized by numerous neuronal intranuclear inclusion bodies similar to those found in polyglutamine repeat diseases. Previously, we found that the intranuclear inclusion bodies are intensely immunopositive for SUMO-1, a protein which covalently conjugates to other proteins in a similar way to ubiquitin. To identify the SUMO-1-associated proteins in the inclusion bodies, we isolated intranuclear inclusion bodies from fresh, frozen brain tissue of a case with familial neuronal intranuclear inclusion disease and solubilized the proteins. SUMO-1-associated inclusion body proteins were then immunocaptured using an anti-SUMO-1 antibody. The proteins, NSF, dynamin-1 and Unc-18-1 (rbSEC1), involved in membrane trafficking of proteins, and the chaperone HSP90, were identified following anti-SUMO-1-immunocapture by using tandem mass spectrometry and database searching. Immunohistochemistry of brain sections and crude brain homogenates of three cases of familial neuronal intranuclear inclusion disease confirmed the presence of these proteins in intranuclear inclusions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18836734     DOI: 10.1007/s00401-008-0437-4

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  20 in total

Review 1.  SUMO rules: regulatory concepts and their implication in neurologic functions.

Authors:  Mathias Droescher; Viduth K Chaugule; Andrea Pichler
Journal:  Neuromolecular Med       Date:  2013-08-30       Impact factor: 3.843

2.  Proteomics analysis of nucleolar SUMO-1 target proteins upon proteasome inhibition.

Authors:  Vittoria Matafora; Alfonsina D'Amato; Silvia Mori; Francesco Blasi; Angela Bachi
Journal:  Mol Cell Proteomics       Date:  2009-07-12       Impact factor: 5.911

3.  Urodynamic Assessment of Neuronal Intranuclear Inclusion Disease.

Authors:  Yosuke Aiba; Ryuji Sakakibara; Fang-Ching Lee; Fuyuki Tateno
Journal:  Eur Neurol       Date:  2020-07-09       Impact factor: 1.710

4.  Copy number variation in pediatric multiple sclerosis.

Authors:  J P McElroy; L B Krupp; B A Johnson; J L McCauley; Z Qi; S J Caillier; P A Gourraud; J Yu; L Nathanson; A L Belman; S L Hauser; E Waubant; D J Hedges; J R Oksenberg
Journal:  Mult Scler       Date:  2012-12-13       Impact factor: 6.312

5.  Sumoylated HSP90 is a dominantly inherited plasma cell dyscrasias risk factor.

Authors:  Klaus-Dieter Preuss; Michael Pfreundschuh; Martin Weigert; Natalie Fadle; Evi Regitz; Boris Kubuschok
Journal:  J Clin Invest       Date:  2014-12-08       Impact factor: 14.808

6.  SUMO-1 is associated with a subset of lysosomes in glial protein aggregate diseases.

Authors:  Mathew B Wong; Jacob Goodwin; Anwar Norazit; Adrian C B Meedeniya; Christiane Richter-Landsberg; Wei Ping Gai; Dean L Pountney
Journal:  Neurotox Res       Date:  2012-11-15       Impact factor: 3.911

7.  Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitors.

Authors:  Mehdi Mollapour; Dimitra Bourboulia; Kristin Beebe; Mark R Woodford; Sigrun Polier; Anthony Hoang; Raju Chelluri; Yu Li; Ailan Guo; Min-Jung Lee; Elham Fotooh-Abadi; Sahar Khan; Thomas Prince; Naoto Miyajima; Soichiro Yoshida; Shinji Tsutsumi; Wanping Xu; Barry Panaretou; William G Stetler-Stevenson; Gennady Bratslavsky; Jane B Trepel; Chrisostomos Prodromou; Len Neckers
Journal:  Mol Cell       Date:  2014-01-23       Impact factor: 17.970

8.  SUMOylation of the mitochondrial fission protein Drp1 occurs at multiple nonconsensus sites within the B domain and is linked to its activity cycle.

Authors:  Claudia Figueroa-Romero; Jorge A Iñiguez-Lluhí; Julia Stadler; Chuang-Rung Chang; Damien Arnoult; Peter J Keller; Yu Hong; Craig Blackstone; Eva L Feldman
Journal:  FASEB J       Date:  2009-07-28       Impact factor: 5.191

Review 9.  SUMO and Parkinson's disease.

Authors:  Katrin Eckermann
Journal:  Neuromolecular Med       Date:  2013-08-25       Impact factor: 3.843

Review 10.  Protein SUMOylation in neuropathological conditions.

Authors:  Dina B Anderson; Kevin A Wilkinson; Jeremy M Henley
Journal:  Drug News Perspect       Date:  2009-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.